Drugs / BMS-986326
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06248814 | Mar 2024 → Nov 2025 | atopic eczema | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06013995 | Sep 2023 → Apr 2026 | lupus erythematosus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04736134 | Mar 2021 → Mar 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06248814 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT04736134 ↗ |